Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder

por Lipkovich, Ilya, Jacobson, Jennie G, Hardy, Thomas A, Hoffmann, Vicki Poole
Publicado 2008

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaff...

por Deberdt, Walter, Lipkovich, Ilya, Heinloth, Alexandra N, Liu, Lin, Kollack-Walker, Sara, Edwards, Sara E, Hoffmann, Vicki Poole, Hardy, Thomas A
Publicado 2008

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist

por Guzman, Cristina B., Duvvuru, Suman, Akkari, Anthony, Bhatnagar, Pallav, Battioui, Chakib, Foster, Wendra, Zhang, Xiaotian Michelle, Shankar, Sudha S., Deeg, Mark A., Chalasani, Naga, Hardy, Thomas A., Kazda, Christof M., Pillai, Sreekumar G.
Publicado 2018

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:12...

por Kazda, Christof M., Ding, Ying, Kelly, Ronan P., Garhyan, Parag, Shi, Chunxue, Lim, Chay Ngee, Fu, Haoda, Watson, David E., Lewin, Andrew J., Landschulz, William H., Deeg, Mark A., Moller, David E., Hardy, Thomas A.
Publicado 2017